MOTS-c

At a glance

---

What is MOTS-c?

MOTS-c stands for Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c. It is a 16-amino-acid peptide encoded not in your nuclear DNA — the genome most people think of — but in your mitochondrial DNA. This makes it part of a small but growing family of molecules called mitochondrial-derived peptides (MDPs).^[1]

The peptide was discovered in 2015 by Changhan David Lee and Pinchas Cohen at the University of Southern California. They found that this short sequence, encoded within the mitochondrial 12S rRNA gene, was translated into an active signaling molecule that could regulate metabolism throughout the entire body — not just within the mitochondria that produced it.^[1]

This was a paradigm-shifting finding. Mitochondria were long thought of as passive energy generators — the "powerhouses of the cell." The discovery of MOTS-c (and its cousin, humanin, discovered in 2001) revealed that mitochondria actively send signals to the rest of the cell and body, including all the way to the nucleus, to regulate gene expression and metabolic function.

MOTS-c is sometimes called a "mitokine" — a mitochondrial hormone. Unlike traditional peptides that are encoded in nuclear DNA and produced in specific glands, MOTS-c is produced from mitochondrial DNA and has been detected in blood circulation, skeletal muscle, and other tissues. Its levels decline with age, which has fueled interest in it as a longevity target.

---

How it works

In plain terms, MOTS-c appears to activate the same cellular pathways that exercise does. It flips a metabolic switch — AMPK — that tells cells to shift into an energy-conserving, repair-oriented mode. This is the same pathway activated by exercise, fasting, and the diabetes drug metformin.^[1]

Think of MOTS-c as a molecular messenger from your mitochondria to the rest of your cell, saying: "We need to adapt to metabolic stress. Turn on the repair and efficiency programs."

Detailed mechanism (for advanced readers)

MOTS-c's mechanism of action involves several interconnected pathways:

• Folate-AICAR-AMPK pathway: MOTS-c inhibits the folate cycle and its tethered de novo purine biosynthesis pathway. This leads to accumulation of the purine synthesis intermediate AICAR, which is a well-known AMPK activator. This is the primary mechanism identified in the discovery paper.^[1]
• Nuclear translocation: Under metabolic stress (glucose restriction, serum deprivation, oxidative stress), MOTS-c rapidly translocates from the cytoplasm to the nucleus in as little as 30 minutes. In the nucleus, it interacts with stress-responsive transcription factors including NRF2 and regulates antioxidant response element (ARE) genes. This represents a novel form of mitonuclear communication — the mitochondrial genome actively controlling nuclear gene expression.^[2]
• Myostatin reduction: MOTS-c reduces myostatin (a negative regulator of muscle growth) via the CK2-PTEN-mTORC2-AKT-FOXO1 signaling axis. By inhibiting FOXO1, a transcription factor for muscle wasting genes, MOTS-c protects against muscle atrophy.^[4]
• GLUT4 upregulation: Through AMPK activation, MOTS-c upregulates glucose transporter type 4 (GLUT4) in skeletal muscle, enhancing glucose uptake — the same effect that exercise produces.
• Membrane repair: Recent research shows MOTS-c facilitates plasma membrane repair by promoting the translocation of TRIM72 to damaged membranes, with cardioprotective implications.

How it differs from related compounds:

• Unlike NAD+ (which is a coenzyme fueling hundreds of metabolic reactions), MOTS-c is a signaling peptide that activates specific pathways
• Unlike metformin (which also activates AMPK through Complex I inhibition), MOTS-c activates AMPK through the folate-AICAR route
• Unlike humanin (a fellow mitochondrial-derived peptide), MOTS-c primarily targets metabolic and exercise pathways rather than neuroprotective ones

---

What the research says

MOTS-c has one of the strongest mechanistic stories in the research peptide space — a genuine paradigm shift in how we understand mitochondrial signaling. But the clinical evidence trail is almost nonexistent. Not a single completed human trial of native MOTS-c exists.

Research timeline

Since its discovery in 2015, MOTS-c research has moved quickly in the preclinical space but barely begun in humans:

Human clinical trials

The human clinical evidence for MOTS-c is extremely thin. There is exactly one trial, and it tested a modified analog — not native MOTS-c:

Beyond this single trial, human data on MOTS-c is limited to:

• Observational measurements of endogenous MOTS-c levels showing they decline with age (11-21% lower in middle/older adults) and rise transiently with exercise^[3]
• Epidemiological association between a MOTS-c polymorphism and Type 2 diabetes risk across 27,527 subjects^[5]
• No registered clinical trials of native MOTS-c on ClinicalTrials.gov as of March 2026

Animal studies

The preclinical literature for MOTS-c is substantially stronger than the human data. While not as large as the BPC-157 literature (100+ studies), the MOTS-c evidence base is growing and has several strengths — including publication in top-tier journals (Cell Metabolism, Nature Communications) and increasing independent replication.^[6]

Key findings by area

• Metabolic homeostasis: MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance and obesity. Acts through the folate-AICAR-AMPK pathway to enhance glucose metabolism.^[1]
• Exercise mimetic effects: Late-life MOTS-c treatment (3x/week) significantly enhanced physical performance in young, middle-aged, and old mice. Improved running endurance, muscle metabolism, and healthspan.^[3]
• Muscle protection: Reduced myostatin expression and muscle atrophy signaling in diet-induced obese mice. Plasma MOTS-c levels inversely correlated with myostatin in humans (observational).^[4]
• Nuclear gene regulation: MOTS-c translocates to the nucleus under metabolic stress, interacting with NRF2 to regulate antioxidant response genes — a novel form of mitonuclear communication.^[2]
• Pancreatic protection: MOTS-c prevents islet cell senescence and delays diabetes onset in mouse models (independent lab, 2025).^[10]
• Membrane repair: MOTS-c facilitates plasma membrane repair via TRIM72 translocation, preserving heart function after ischemia/reperfusion injury in mice.

---

What the evidence shows

MOTS-c is marketed with several specific claims. Here is what the published research actually supports:

---

Safety & side effects

What research shows

There is no controlled human safety data for native MOTS-c. The entirety of what we know about MOTS-c safety in humans comes from the CB4211 analog trial, where 85 subjects received a modified version for short periods with no serious adverse events.^[9]

MOTS-c is an endogenous peptide — your body naturally produces it. This provides some theoretical safety baseline, but it does not mean that injecting exogenous MOTS-c at supraphysiological doses is safe. Many endogenous hormones (insulin, growth hormone, testosterone) can cause serious harm when administered at doses exceeding natural levels.

Community-reported side effects

Among people who have used MOTS-c obtained from research peptide vendors, commonly reported effects include:

• Injection-site redness, itching, or tenderness
• Mild flushing
• Headache
• Fatigue
• Mild nausea or stomach discomfort
• Insomnia (less common)
• Increased heart rate or palpitations (rare)

These are self-reported and uncontrolled. They may reflect MOTS-c effects, contamination, or placebo/nocebo responses.

Theoretical risks

Theoretical contraindications and concerns

Theoretical contraindications (based on mechanism of action, not clinical data):

• Pregnancy and breastfeeding (no safety data whatsoever)
• Active cancer (AMPK activation has complex, context-dependent effects on cancer — sometimes protective, sometimes permissive)
• Individuals on metformin or other AMPK activators (additive AMPK activation could cause hypoglycemia or lactic acidosis)
• Severe hypoglycemia risk (MOTS-c enhances glucose uptake)

Drug interactions: No formal interaction studies exist. Theoretical interactions with:

• Metformin and other diabetes medications (additive glucose-lowering)
• AMPK-activating drugs
• Folate metabolism-affecting drugs (MOTS-c inhibits the folate cycle)

Contamination risk: MOTS-c purchased from research peptide vendors is not pharmaceutical-grade. Purity, sterility, and dosing accuracy are unverified. This is arguably the largest practical safety concern for users.

---

How people use it

MOTS-c is most commonly discussed in the context of longevity, metabolic health, and exercise optimization. Here is what the landscape of use looks like — with important caveats.

Administration routes

• Subcutaneous injection (most common): The standard route discussed in longevity communities and by anti-aging clinics.
• Intravenous injection: Less common. No data on IV MOTS-c pharmacokinetics.
• Oral use is not established: Unlike BPC-157 (which shows gastric stability), MOTS-c as a small peptide would likely be degraded in the GI tract. No oral formulation data exists.

Common stacking context

In community practice, MOTS-c is often discussed alongside other longevity-focused compounds:

• MOTS-c + NAD+ precursors (NMN/NR) — a "mitochondrial stack" targeting multiple mitochondrial pathways. No clinical data for the combination.
• MOTS-c + Humanin — combining two mitochondrial-derived peptides. Theoretical complementarity (metabolism + neuroprotection). No combination data.
• MOTS-c + metformin — both activate AMPK, raising theoretical concerns about additive hypoglycemia risk. No safety data for the combination.

All stacking protocols are community-derived and have not been studied in any controlled setting.

---

Legal & regulatory status

As of March 2026:

FDA status

MOTS-c is not FDA-approved for any indication. It is classified as a research compound and is not eligible for compounding under 503A/503B pathways. No Investigational New Drug (IND) application is publicly listed for native MOTS-c.

The only clinical development effort was CohBar's CB4211 (a modified MOTS-c analog), which completed Phase 1a/1b for NAFLD. The company has since restructured, and the future of clinical development is uncertain.^[9]

WADA / USADA status

MOTS-c is prohibited at all times under WADA Section 4.4 Metabolic Modulators, specifically Section 4.4.1 as an activator of AMP-activated protein kinase (AMPK). No Therapeutic Use Exemption (TUE) is available because there is no approved therapeutic use. Athletes testing positive face a standard 4-year ban.^[12]

International status

MOTS-c is not approved for clinical use in any country. It is sold as a "research peptide" by online vendors and marketed by longevity and anti-aging clinics without regulatory approval.

---

How MOTS-c compares

To put MOTS-c in context within the longevity peptide space, here is how it compares to a related mitochondrial-targeting compound:

The comparison is instructive. Both MOTS-c and metformin activate AMPK. But metformin has been used safely in millions of patients for decades, has well-characterized side effects, and is FDA-approved. MOTS-c has the more elegant mechanism (a natural mitochondrial signal vs. a synthetic drug) but essentially zero human proof that it works or is safe when administered exogenously.

For people interested in AMPK activation, metformin is the evidence-based option. MOTS-c may eventually prove to be superior — but that evidence does not yet exist.

---

The mitochondrial-derived peptide family

MOTS-c does not exist in isolation. It belongs to a growing family of mitochondrial-derived peptides (MDPs) — small bioactive molecules encoded in mitochondrial DNA:

Known mitochondrial-derived peptides

• Humanin — Discovered in 2001. A 24-amino-acid peptide encoded in the mitochondrial 16S rRNA gene. Primarily neuroprotective. Shows effects against Alzheimer's disease-related toxins and promotes cell survival. More extensively studied than MOTS-c.
• MOTS-c — Discovered in 2015. A 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. Primarily metabolic. Activates AMPK, mimics exercise effects. The "exercise mimetic" of the MDP family.
• SHLP1-6 (Small Humanin-Like Peptides) — Six additional peptides identified in the mitochondrial 16S rRNA gene. Less studied than humanin or MOTS-c. SHLP2 improves insulin sensitivity; SHLP3 supports mitochondrial health and reduces reactive oxygen species.

The existence of this family suggests that the mitochondrial genome encodes a broader signaling repertoire than previously recognized. The 8 known MDPs collectively regulate metabolism, cell survival, inflammation, and tissue repair — suggesting mitochondria function as active signaling organelles, not just energy generators.

---

Related content

Guide

What Are Peptides?

A foundational primer — helpful for understanding MOTS-c's unique mitochondrial origin.

News

Kennedy Peptide Reclassification

Regulatory changes that could affect access to research peptides like MOTS-c.

Tool

Reconstitution Calculator

Calculate exact syringe units for MOTS-c preparation.

---

References

1. [1]

   Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab. 2015. 21(3):443–454 DOI PubMedAnimal study

   Landmark discovery paper from the Cohen/Lee lab at USC. Identified MOTS-c and its metabolic effects in mice via the folate-AICAR-AMPK pathway.

2. [2]

   Lee C, Kim KH, Cohen P. “The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.” Cell Metab. 2018. 28(3):516–524.e7 DOI PubMedAnimal study

   Key mechanistic paper demonstrating MOTS-c nuclear translocation under metabolic stress via AMPK. Novel mitonuclear communication pathway.

3. [3]

   Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benber B, Veli PA, Lee C. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nat Commun. 2021. 12(1):470 DOI PubMedAnimal study

   Key exercise paper. Mouse intervention + human observational MOTS-c measurements. Exercise induces endogenous MOTS-c in human muscle/circulation.

4. [4]

   Kim SJ, Miller B, Kumagai H, Silverstein AR, Flores M, Yen K. “MOTS-c reduces myostatin and muscle atrophy signaling.” Am J Physiol Endocrinol Metab. 2021. 320(4):E680–E692 DOI PubMedAnimal study

   Shows MOTS-c reduces myostatin via CK2-PTEN-mTORC2-AKT-FOXO1 pathway. Inverse correlation between plasma MOTS-c and myostatin in humans (observational).

5. [5]

   Kim SJ, Miller B, Kumagai H, Yen K, Cohen P. “A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.” Aging (Albany NY). 2021. 13(2):1692–1717 DOI PubMedReview

   Meta-analysis of 27,527 subjects across 3 cohorts. Asian-specific m.1382A>C polymorphism (K14Q) in MOTS-c increases T2D risk in sedentary males.

6. [6]

   Li Q, Lu H, Hu G, Ye Z, Zhai D, Yan Z, Wang L, Xiang A, Lu Z. “Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging.” J Transl Med. 2023. 21(1):36 DOI PubMedReview

   Comprehensive review of MOTS-c mechanisms including AMPK activation, stress response, metabolism, and aging.

7. [7]

   Kim SJ, Mehta HH, Engemann SC, Gao Q, Yen K, Cohen P. “Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases.” Diabetes Metab J. 2023. 47(3):315–326 DOI PubMedReview

   Review from the discoverer’s lab on MOTS-c in diabetes and aging. Authoritative but potential positive framing bias.

8. [8]

   Kumagai H, Miller B, Kim SJ, Leelaprachakul N, Kikuchi N, Yen K, Cohen P. “MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.” Int J Mol Sci. 2022. 23(20):11991 DOI PubMedReview

   Review covering MOTS-c circulating level decline with age (11–21% lower in middle/older groups) and role in age-related diseases.

9. [9]

   CohBar Inc.. “Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (NCT03998514).” 2021. LinkPilot study

   Industry-sponsored. Phase 1a: 65 healthy adults. Phase 1b: 20 obese NAFLD subjects (11 active, 9 placebo). 4-week duration. CB4211 is a modified analog, not native MOTS-c.

10. [10]

    Wu Y, et al.. “Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes.” Exp Mol Med. 2025. DOI PubMedAnimal study

    Independent lab. Shows MOTS-c prevents islet cell senescence via metabolite transport regulation. Published in Nature-affiliated journal.

11. [11]

    Mohtashami Z, Singh MK, Salimiaghdam N, Ozber M, Kenney MC, Khorram O. “MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.” Front Endocrinol. 2023. 14:1120533 DOIReview

    Independent review providing balanced overview of MOTS-c therapeutic potential across metabolism, aging, cancer, and cardiovascular disease.

12. [12]

    U.S. Anti-Doping Agency. “What is the MOTS-c peptide?.” 2024. Link

    Official USADA statement confirming MOTS-c is prohibited under WADA Section 4.4.1 (AMPK activators) at all times.

---